ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
관절통 시장 규모는 향후 몇 년간 강력한 성장이 전망될 예정입니다. 예측 기간의 성장은 관절통에 대한 인식 증가, 노인 인구 증가, 의료 인프라 확대, 최소 침습적 치료에 대한 수요 증가, 스포츠 부상 유병률 증가에 의해 주도될 것으로 예상됩니다.
류마티스 관절염 증가는 향후 몇 년 동안 관절통 시장의 성장을 가속할 것으로 예측됩니다. 흡연이나 오염 등의 환경 요인 등의 요인에 기인하고 있습니다 류마티스 관절염는 만성적인 관절의 염증을 일으켜, 통증, 경직, 진행성의 손상을 초래하는 것으로, 관절통의 일인이 되고 있습니다. 예를 들면, 2024년 2월, 호주에 거점으로 있는 Arthritis Australia는 2040년까지 호주에서 관절염 환자 수가 2025년 411만명에서 539만명으로 증가하고, 류마티스 관절염 환자 수는 74만 8,721명에 이를 것으로 예측했습니다.
관절통 시장의 각 회사는 장기적인 통증 완화와 관절 기능 개선을 가져오는 RMAT 지정 유전자 치료 등의 혁신적인 치료법의 개발에 주력하고 있습니다. RMAT 지정 유전자 치료제는 심각하거나 생명을 위협하는 질환에 대한 유전자 치료제의 개발 및 심사를 가속화하는 FDA의 재생 의학 첨단 치료(RMAT) 지정을 받은 치료제를 말합니다. 2024년 3월, 미국에 본사를 둔 제약 회사인 파시라 바이오사이언스는 미국 식품의약국(FDA)으로부터 자사 제품 PCRX-201(에네킨라진 인자데노벡)에 대한 RMAT 지정을 받았습니다. PCRX-201은 인터루킨-1 수용체 길항제(IL-1Ra)를 생성하는 헬퍼 의존성 아데노바이러스(HDAd)를 사용하여 무릎 골관절염을 치료하도록 설계된 혁신적인 관절 내 유전자 치료 후보물질입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 관절통 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 관절통 시장 : 성장률 분석
세계의 관절통 시장 실적 : 규모와 성장(2019-2024년)
세계의 관절통 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 관절통 전체 시장(TAM)
제6장 시장 세분화
세계의 관절통 시장 : 원인별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
골관절염
류마티스 관절염
통풍
건선성 관절염
루푸스
부상
감염
기타 원인
세계의 관절통 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
약물 치료
치료법
외과적 개입
생활습관 및 가정요법
세계의 관절통 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구용
주사제
국소용
경피용
세계의 관절통 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 관절통 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
홈케어
재활센터
세계의 관절통 시장 : 골관절염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
무릎 골관절염
고관절 골관절염
손 골관절염
척추 골관절염
어깨 골관절염
세계의 관절통 시장 : 류마티스 관절염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
혈청 양성 류마티스 관절염
혈청 음성 류마티스 관절염
청소년 류마티스 관절염
조기 발병 류마티스 관절염
세계의 관절통 시장 : 통풍 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
원발성 통풍
이차성 통풍
통풍성 관절염
세계의 관절통 시장 : 건선성 관절염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
대칭성 건선성 관절염
비대칭성 건선성 관절염
건선성 척추염
원위 지간 우세 건선성 관절염
세계의 관절통 시장 : 루푸스 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
전신성 홍반성 루푸스(SLE)
원판상 홍반성 루푸스
약물 유발성 루푸스
신생아 루푸스
세계의 관절통 시장 : 부상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
스포츠 관련 부상
외상 및 골절
염좌 및 긴장
힘줄 또는 인대 손상
세계의 관절통 시장 : 감염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
패혈성 관절염
바이러스성 관절염
박테리아 감염
진균 감염
세계의 관절통 시장 : 기타 원인 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
섬유근육통
과사용 부상
유육종증
강직성 척추염
결정유발성 관절염
제7장 지역별/국가별 분석
세계의 관절통 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 관절통 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
관절통 시장 : 경쟁 구도
관절통 시장 : 기업 프로파일
Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson Services Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca PLC
Novartis AG
GlaxoSmithKline PLC
Eli Lilly and Company
Amgen Inc.
Teva Pharmaceutical Industries Ltd.
Regeneron Pharmaceuticals Inc.
Astellas Pharma Inc.
Biogen Inc.
UCB SA
Hikma Pharmaceuticals PLC
Ferring Pharmaceuticals
KD Pharma Group SA
SI-BONE Inc.
Xalud Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
관절통 시장(2029년) : 새로운 기회를 제공하는 국가
관절통 시장(2029년) : 새로운 기회를 제공하는 부문
관절통 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Arthralgia refers to pain in one or more joints, usually without inflammation, and can stem from various causes, including infections, autoimmune diseases, or injuries. It is a symptom rather than a standalone condition, often indicating an underlying health issue affecting the joints.
The primary causes of arthralgia include osteoarthritis, rheumatoid arthritis, gout, psoriatic arthritis, lupus, injuries, infections, and other contributing factors. Osteoarthritis is a degenerative joint disease that develops when the protective cartilage cushioning the ends of bones gradually wears down. A range of treatment options is available, including medications, therapies, surgical interventions, and lifestyle or home remedies. These treatments can be administered through different methods, such as oral, injectable, topical, and transdermal routes. They are distributed via hospital pharmacies, retail pharmacies, and online pharmacies and are used across various settings, including hospitals, clinics, home care environments, and rehabilitation centers.
The arthralgia market research report is one of a series of new reports from The Business Research Company that provides arthralgia market statistics, including the arthralgia industry global market size, regional shares, competitors with the arthralgia market share, detailed arthralgia market segments, market trends, and opportunities, and any further data you may need to thrive in the arthralgia industry. This arthralgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The arthralgia market size has grown strongly in recent years. It will grow from $5.20 billion in 2024 to $5.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising prevalence of autoimmune diseases, the increasing incidence of various associated risk factors, the growing rates of obesity, the higher prevalence of arthralgia, and the increasing occurrence of joint disorders.
The arthralgia market size is expected to see strong growth in the next few years. It will grow to $7.73 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period is expected to be driven by increasing awareness of arthralgia, a growing geriatric population, expanding healthcare infrastructure, rising demand for minimally invasive treatments, and the increasing prevalence of sports injuries. Key trends during this period include the integration of digital health solutions, the development of novel therapies and cell therapies, advancements in medical technology, and increased investment in research and development.
The increasing incidence of rheumatoid arthritis is expected to drive the growth of the arthralgia market in the coming years. Rheumatoid arthritis is a chronic autoimmune condition that primarily impacts the joints, causing inflammation, pain, and potential joint damage. The rise in rheumatoid arthritis cases can be attributed to factors such as an aging population, genetic predisposition, lifestyle changes, and environmental factors such as smoking and pollution. Rheumatoid arthritis contributes to arthralgia by causing chronic joint inflammation, leading to pain, stiffness, and progressive damage. For example, in February 2024, Arthritis Australia, a non-profit organization based in Australia, projected that by 2040, arthritis cases in Australia would increase to 5.39 million from 4.11 million in 2025, with rheumatoid arthritis cases reaching 748,721. Consequently, the growing number of rheumatoid arthritis cases is fueling the expansion of the arthralgia market.
Companies in the arthralgia market are focusing on developing innovative treatments, such as RMAT-designated gene therapies, to provide long-term pain relief and improved joint function. RMAT-designated gene therapy refers to a treatment that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which accelerates the development and review of gene therapies for serious or life-threatening conditions. In March 2024, Pacira BioSciences Inc., a US-based pharmaceutical company, received RMAT designation for its product PCRX-201 (enekinragene inzadenovec) from the U.S. Food and Drug Administration (FDA). PCRX-201 is an innovative intra-articular gene therapy candidate designed to treat knee osteoarthritis using a helper-dependent adenovirus (HDAd) to produce interleukin-1 receptor antagonists (IL-1Ra). Pacira emphasized the promising preliminary clinical results, suggesting that PCRX-201 could become a potential disease-modifying treatment for osteoarthritis.
In November 2023, Nevro Corp., a US-based medical device company, acquired Vyrsa Technologies for $75 million. This acquisition allows Nevro to expand its chronic pain treatment portfolio by incorporating Vyrsa Technologies' minimally invasive SI joint fusion devices. By enhancing its market presence, Nevro aims to provide advanced solutions for long-term pain relief to patients suffering from chronic sacroiliac (SI) joint pain. Vyrsa Technologies, a US-based company, specializes in treating arthralgia, specifically addressing chronic SI joint pain.
Major players in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation, and Vitazan Herbs and Vitamins Inc.
North America was the largest region in the arthralgia market in 2024. The regions covered in arthralgia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the arthralgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The arthralgia market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, physical rehabilitation programs, and supportive services. The market value includes the value of related goods sold by the service provider or included within the service offering. The arthralgia market also includes sales of musculoskeletal diagnostic tools, biologic drugs, anti-inflammatory drugs, and regenerative therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Arthralgia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on arthralgia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for arthralgia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The arthralgia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Cause: Osteoarthritis; Rheumatoid Arthritis; Gout; Psoriatic Arthritis; Lupus; Injuries; Infections; Other Causes
2) By Treatment Type: Medications; Therapies; Surgical Interventions; Lifestyle And Home Remedies
3) By Route Of Administration: Oral; Injectable; Topical; Transdermal
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospital; Clinics; Homecare Settings; Rehabilitation Centers
Subsegments:
1) By Osteoarthritis: Knee Osteoarthritis; Hip Osteoarthritis; Hand Osteoarthritis; Spine Osteoarthritis; Shoulder Osteoarthritis
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Arthralgia Market Characteristics
3. Arthralgia Market Trends And Strategies
4. Arthralgia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Arthralgia Growth Analysis And Strategic Analysis Framework
5.1. Global Arthralgia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Arthralgia Market Growth Rate Analysis
5.4. Global Arthralgia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Arthralgia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Arthralgia Total Addressable Market (TAM)
6. Arthralgia Market Segmentation
6.1. Global Arthralgia Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Osteoarthritis
Rheumatoid Arthritis
Gout
Psoriatic Arthritis
Lupus
Injuries
Infections
Other Causes
6.2. Global Arthralgia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications
Therapies
Surgical Interventions
Lifestyle And Home Remedies
6.3. Global Arthralgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Topical
Transdermal
6.4. Global Arthralgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Arthralgia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Clinics
Homecare Settings
Rehabilitation Centers
6.6. Global Arthralgia Market, Sub-Segmentation Of Osteoarthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Spine Osteoarthritis
Shoulder Osteoarthritis
6.7. Global Arthralgia Market, Sub-Segmentation Of Rheumatoid Arthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Seropositive Rheumatoid Arthritis
Seronegative Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Early-Onset Rheumatoid Arthritis
6.8. Global Arthralgia Market, Sub-Segmentation Of Gout, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary Gout
Secondary Gout
Gouty Arthritis
6.9. Global Arthralgia Market, Sub-Segmentation Of Psoriatic Arthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
